LLY

1,077.28

-2.33%↓

JNJ

221.91

-1.45%↓

ABBV

213.42

-2.08%↓

UNH

382.1

+0.91%↑

MRK

115.62

-2.51%↓

LLY

1,077.28

-2.33%↓

JNJ

221.91

-1.45%↓

ABBV

213.42

-2.08%↓

UNH

382.1

+0.91%↑

MRK

115.62

-2.51%↓

LLY

1,077.28

-2.33%↓

JNJ

221.91

-1.45%↓

ABBV

213.42

-2.08%↓

UNH

382.1

+0.91%↑

MRK

115.62

-2.51%↓

LLY

1,077.28

-2.33%↓

JNJ

221.91

-1.45%↓

ABBV

213.42

-2.08%↓

UNH

382.1

+0.91%↑

MRK

115.62

-2.51%↓

LLY

1,077.28

-2.33%↓

JNJ

221.91

-1.45%↓

ABBV

213.42

-2.08%↓

UNH

382.1

+0.91%↑

MRK

115.62

-2.51%↓

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Avatud

SektorTervishoid

2.65 -6.36

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.55

Max

2.83

Põhinäitajad
By Trading Economics
Sissetulek	1.2M -31M
Müük	-70K 1.3M
Aktsiakasum	-0.26
Kasumimarginaal	-2,402.848
Töötajad	161
EBITDA	12M -30M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+55.63% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	10. aug 2026

Turustatistika
By TradingEconomics
Turukapital	8.8M 262M
Eelmine avamishind	9.01
Eelmine sulgemishind	2.65

Uudiste sentiment

By Acuity

34%

66%

67 / 344 Pingereas Healthcare

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

31. mai 2026, 23:44 UTC

Market Talk

Nikkei May Remain Rangebound Amid Middle East Uncertainty -- Market Talk

31. mai 2026, 23:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

31. mai 2026, 23:36 UTC

Market Talk

Oil Rises Amid Few Signs of Strait of Hormuz's Reopening -- Market Talk

31. mai 2026, 23:36 UTC

Market Talk

Watch for Data-Center Investment in Australia's 1Q GDP Print -- Market Talk

31. mai 2026, 22:54 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Hathaway to Buy Homebuilder Taylor Morrison for $6.8 Billion -- WSJ

29. mai 2026, 23:08 UTC

Omandamised, ülevõtmised, äriostud

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29. mai 2026, 23:06 UTC

Omandamised, ülevõtmised, äriostud

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29. mai 2026, 20:53 UTC

Tulu

Oil Declines Lift Stocks to Fresh Records -- WSJ

29. mai 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

29. mai 2026, 20:33 UTC

Market Talk

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29. mai 2026, 20:11 UTC

Tulu

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29. mai 2026, 19:47 UTC

Tulu

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29. mai 2026, 19:36 UTC

Market Talk

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29. mai 2026, 19:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

29. mai 2026, 19:34 UTC

Market Talk

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29. mai 2026, 19:22 UTC

Market Talk

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29. mai 2026, 19:05 UTC

Omandamised, ülevõtmised, äriostud

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29. mai 2026, 18:19 UTC

Market Talk

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29. mai 2026, 18:12 UTC

Omandamised, ülevõtmised, äriostud

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29. mai 2026, 18:11 UTC

Market Talk

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29. mai 2026, 18:10 UTC

Market Talk

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29. mai 2026, 17:55 UTC

Tulu

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29. mai 2026, 17:55 UTC

Market Talk

NEAR Protocol Nearly Doubles in May -- Market Talk

29. mai 2026, 17:38 UTC

Market Talk

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29. mai 2026, 17:00 UTC

Tulu

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29. mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

29. mai 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

29. mai 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

29. mai 2026, 16:02 UTC

Market Talk

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29. mai 2026, 15:55 UTC

Market Talk

Global Equities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

55.63% tõus

12 kuu keskmine prognoos

Keskmine 4.42 USD 55.63%

Kõrge 7 USD

Madal 2.2 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

67 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.